General news

Radiomics installed in CHU Liege and University of Florence the first machines required for the connection to the distributed learning network in the framework of DRAGON. This project, funded by the European Commission’s Horizon 2020 program Innovative Medicine Initiative (IMI) aimed at using artificial intelligence (AI) and machine learning to develop decision support systems capable of delivering a more precise coronavirus diagnosis and more accurate predictions of patient outcomes.

La société Radiomics est heureuse et fière d’annoncer la visite, ce 19 mai 2021, de Monsieur Mathieu Michel, Secrétaire d’Etat fédéral belge à la Digitalisation, chargé de la Simplification administrative, de la Protection de la vie privée et de la Régie des Bâtiments.

Radiomics is pleased to announce the official opening of its first North American sales and support office with the support of the Walloon investment support agency AWEX. The new office, established in Toronto, Ontario will kick-start the company's partnerships in the area, better accommodating pharma companies and clinicians’ needs through North America-based team members.

Wim Vos CEO of Radiomics guest at Tekna Talks: Drug discovery – from airflow around a bobsleigh to airflow in the lungs.

The TIGER consortium led by eTheRNA immunotherapies and including Radiomics, is awarded an EU Commission’s grant for an HPV 16+ vaccine clinical trial

L’Europa ha lanciato un nuovo progetto chiamato Dragon, per applicare l’intelligenza artificiale alla battaglia contro il COVID-19.

A new method to map the inner ear using artificial intelligence (AI). That is what the Belgian start-up Radiomics has developed in close collaboration with doctors and scientists from Maastricht UMC +, Maastricht University, Antwerp University Hospital (UZA) and the University of Antwerp.

Radiomics together with UZAntwerpen and UMaastricht, has developed a novel tool for the automatic identification of the inner ear on MRI

With great enthusiasm and pride, the OncoRadiomics team today unveils the company's new brand identity: ‘Radiomics’.

OncoRadiomics, spin-off de l’Université de Maastricht installée à Liège et spécialisée dans le développement d’outils innovants de radiométrie, devient Radiomics afin que cette nouvelle identité corresponde davantage à ses projets de développement et ses objectifs de croissance.

Radiomics is glad to start the new year 2021 announcing and welcoming its new Chief Commercial Officer (CCO) Carlos Contreras Meca!

Radiomics developed a fully automated AI framework to extract radiomics features to classify COVID-19 infected patients from standard-of-care medical images (CT).

Presentation of our work on the prospective validation of a radiomics signature for chemoradiotherapy lung cancer patients

The DRAGON project led by Radiomics in partnership with 18 high-tech SMEs, academic research institutes, biotech and pharma partners, affiliated patient-centred organisations and professional societies from Belgium, Italy, the Netherlands, Switzerland and the UK, has been selected for funding by the Innovative Medicines Initiative (IMI), with an evaluation score placing it in the 95% percentile.

Radiomics is glad to welcome its new Chief Medical Officer, Mariaelena Occhipinti!